Özer KANDEMİR, Mustafa BÜYÜKATEŞ, S. Akın TURAN, Sait M. DOĞAN, Mustafa AYDIN, Erol AKTUNÇ, Ahmet DURSUN

Comparison of gene polymorphisms in severe atherosclerotic patients in different age groups

Amaç: Bu çalışma, koroner arter hastalığı bulunan bir grup hastada anjiyotensin dönüştürücü enzim, faktör V, endotelyal nitrik oksit sentaz ve interlökin-6 genetik polimorfızmlerinin birlikteliğini değerlendirmektedir. Gereç ve Yöntem : Hastalar, biri kontrol ve diğer ikisi çalışma grubu 1 ve çalışma grubu 2 olarak, 20'ser kişiden oluşan 3 gruba ayrıldılar. Grup l'e ait hastalar, 40 yasın altında ve ciddi koroner arter hastalığı bulunan hastalardan oluştu. Grup 2'ye ait hastalar, 70 yasın üstünde ve ciddi koroner arter hastalığı olan kişilerden oluştu. Kontrol grubundaki hastalar, 70 yasın üzerinde ve normal koroner arterlere sahip olan kişilerden oluştu. Gruplar arasında anjiyotensin dönüştürücü enzim, faktör V, endotelyal nitrik oksit sentaz ve intcrlökin-6 gen polimorfızmlerine ait allel sıklıkları karşılaştırıldı. Bulgular: Grup 1 ve Grup 2'deki hastalarda tespit edilen, anjiyotensin dönüştürücü enzim, faktör V, endotelyal nitrik oksit sentaz ve interlökin-6 gen polimorfizmlerine ait allel sıklıkları kontrol grubundaki deneklerden elde edilen allel sıklıklarından anlamlı derecede farklı bulunmadı. Faktör V Leiden "A" allel sıklığı, Grup 1 'e ait hastalarda, kontrol grubuna ait hastalardan anlamlı olarak daha yüksek sıklıkta bulundu. Sonuç: Bu çalışmada gerek genç gerekse yaslı kişilerde, anjiyotensin dönüştürücü enzim, faktör V, endotelyal nitrik oksit sentaz ve interlökin-6 genetik polimorfızmleri, koroner arter hastalığı ile bağlantılı bulunmadı. Ancak genç hastalarda, faktör V Leiden "A" allel sıklığı kontrol grubuna ait hastalardan anlamlı olarak daha yüksekti. Bu nedenle, gençlerde görülen koroner arter hastalıklarında protrombotik risk faktörlerinin etiyoloji-de rol aldıkları düşünülebilir.

Ciddi aterosklerozu bulunan farklı yaş gruplarına ait hastalarda görülen gen polimorfizmlerinin karşılaştırılması

Purpose: To evaluate the association of genetic polymorphisms of angiotensin converting enzyme, factor V, endothelial nitric oxide synthase, and interleukinrö in a group of patients that have coronary artery disease. Materials and Methods: Patients were assigned into three groups of 20, one being the control and the other two being the study groups 1 and 2. Group 1 consisted of patients less than 40 years of age with severe coronary artery disease. Group 2 consisted of patients older than 70 years of age with severe coronary artery disease. The control group consisted of patients over 70 years of age with normal coronary arteries. Allele frequencies for angiotensin converting enzyme, factor V, endothelial nitric oxide synthase, and interleukin-6 gene polymorphisms were compared. Results: The allele frequencies for angiotensin converting enzyme, endothelial nitric oxide synthase, and interleukin-6 in groups 1 and 2 were not found to be significantly different from those of the control group. Factor V Leiden 'A' allele frequency was found to be significantly higher in group 1 when compared with the control. Conclusion: In the present study angiotensin converting enzyme, endothelial nitric oxide synthase, and interleukin-6 gene polymorphisms were not associated with coronary artery disease in young or elderly patients. However, in the younger group, Factor V Leiden 'A' allele frequency was significantly higher than that in the control group. Thus, prothrombotic risk factors might be considered an etiological factor for coronary artery disease in younger patients.

PDF

___

1-Cattaruzza M, Guzik TJ, Siodowski W, et al. Shear stress insensitiv-ity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease. Circ Res 2004; 95(8): 841-7.
2-Gimbrone MA, Topper JN, Nagel T, et al. Endothelial dysfunction, hemodynamic forces and atherogenesis. Ann N Y Acad Sci 2000; 902: 230-9.
3-Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419-420.
4-Motulsky AG and Brunzell JD. The genetics of coronary atherosclerosis. In: The Genetic Basis of Common Diseases 1992: 150-169.
5-Rigat B, Hubert C, Corvol P, et al. PCR detection of the insertion/ deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992 Mar 25; 20(6): 1433.
6-Benjafıeld AV, Morris BJ. Association analyses of endothelial nitric oxide synthase gene polymorphisms in essential hypertension. Am J Hypertens 2000; 13(9): 994-8.
7-DeMichele A, Martin AM, Mick R, et al. Interleukin-6 -174G->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63(22): 8051-6.
8-Erdos EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 1990; 16(4): 363-70.
9-Danser AHJ, Schalekamp MADH, Bax WA, et al. Angiotensin-con-verting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation 1995; 92: 1387-1388.
10-Bautista LE, Ardila ME, Gamarra G, et al. Angiotensin-converting enzyme gene polymorphism and risk of myocardial infarction in Colombia. Med Sci Monit 2004; 10(8): CR473-479.
11-Ciecwierz D, Gruchala M, Keita L, et al. Relationship between polymorphism in the angiotensin converting enzyme gene and left ventricular volume and function in subjects below 50 years of age with an angiographically proven coronary heart disease. Med Sci Monit 1998; 4(3): CR453-457.
12-Völzke H, Engel J, Kleine V, et al. Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery. Chest 2002; 122(1): 31-6.
13-Tutun U, Aksoyek A, Ulus AT, et al. Gene polymorphisms in patients below 35 years of age who underwent coronary artery bypass surgery. Coron Artery Dis 2006; 17: 35-39.
14-Hubacek JA, Pitha J, Podrapskâ I, et al. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene in myocardial infarction survivors. Med Sci Monit 2000; 6(3): CR503-506.
15-Furlong B, Henderson AH, Lewis MJ, et al. Endothelium-derived relaxing factor inhibits in yitro platelet aggregation. Br J Pharmacol 1987; 90: 687-92.
16-Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-4655.
17-Hibi K, Ishigami T, Tamura K, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998; 32(3): 521-6.
18-Wang XL, Sim AS, Badenhop RF, et al. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996; 2: 41-45.
19-Heltianu C, Costache G, Gafencu A, et al. Relationship of eNOS gene variants to diseases that have in common an endothelial cell dysfunction. J Cell Mol Med 2005; 9(1): 135-42.
20-Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vase Biol 2001; 21(9): 1458-63.
21-Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772
22-Rus HG, Vlaicu R, Nicilescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996;127:263-271.
23-Gaudino M, Andreotti F, Zaparelli R, et al. The-174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 2003; 108 Suppl 1: II195-9.
24-Heeb MJ, Kojima Y, Greengard JS, et al. Activated protein C resistance: molecular mechanisms based on studies using purified Qln506-factor V. Blood 1995; 85: 3405-3411.
25-Mesci L. The prevalence of factor V Leiden (1691 G-A) mutation in Turkey. Turk J Pediatr 1997; 39: 313-315.
26-Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 1997; 43: 1678-1683.
27-Mahasandana C, Suvatte V, Marlar RA, et al. Neonatal purpura ful-minans associated with homozygous protein S deficiency. Lancet 1990; 35: 61.
28-McColl MD, Tait RC, Walker ID, et al. A symptomatic coinheritance of heterozygous plasminogen deficiency and factor V Leiden mutation. Blood Coagul Fibrinolysis 1997; 8: 195-199.
29-Vallus G, Dlustus B, Acsâdy G, et al. Factor V Leiden and apolipo-protein E genotypes in severe femoropopliteal atherosclerosis with restenosis. Clin Chim Acta 2007; 377(1-2): 256-60.
30-Rosendal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (Resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-2821.
31-Redondo M, Watzke HH, Stucki B, et al. Coagulation factors II, V, VII, and X, prothrombin gene 20210G~>A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vase Biol 1999; 19(4): 1020-5.
32-Van der Bom JG, Bots ML, Haverkate F, et al. Reduced response to activated protein C is associated with increased risk for cerebrovas- cular disease. Ann Intern Med 1996; 125: 265-269.